ACD can configure probes for the various manual and automated assays for INS for RNAscope Assay, or for Basescope Assay compatible for your species of interest.
Cell discovery
2022 Nov 01
Peng, J;Li, F;Wang, J;Wang, C;Jiang, Y;Liu, B;He, J;Yuan, K;Pan, C;Lin, M;Zhou, B;Chen, L;Gao, D;Zhao, Y;
PMID: 36316325 | DOI: 10.1038/s41421-022-00474-3
iScience
2022 Dec 22
O'Leary, TP;Kendrick, RM;Bristow, BN;Sullivan, KE;Wang, L;Clements, J;Lemire, AL;Cembrowski, MS;
PMID: 36425768 | DOI: 10.1016/j.isci.2022.105497
Nature neuroscience
2022 Sep 01
Georgiou, P;Zanos, P;Mou, TM;An, X;Gerhard, DM;Dryanovski, DI;Potter, LE;Highland, JN;Jenne, CE;Stewart, BW;Pultorak, KJ;Yuan, P;Powels, CF;Lovett, J;Pereira, EFR;Clark, SM;Tonelli, LH;Moaddel, R;Zarate, CA;Duman, RS;Thompson, SM;Gould, TD;
PMID: 36042309 | DOI: 10.1038/s41593-022-01146-x
Scientific reports
2022 May 24
Lee, EJ;Saraiva, LR;Hanchate, NK;Ye, X;Asher, G;Ho, J;Buck, LB;
PMID: 35610316 | DOI: 10.1038/s41598-022-12663-x
Clin Cancer Res.
2017 Aug 28
Ennen M, Keime C, Gambi G, Kieny A, Coassolo S, Thibault-Carpentier C, Margerin-Schaller F, Davidson G, Vagne C, Lipsker D, Davidson I.
PMID: 28855355 | DOI: 10.1158/1078-0432.CCR-17-0010
Abstract
PURPOSE:
Understanding tumour heterogeneity is an important challenge in current cancer research. Transcription and epigenetic profiling of cultured melanoma cells have defined at least two distinct cell phenotypes characterised by distinctive gene expression signatures associated with high or low/absent expression of Microphthalmia-associated transcription factor (MITF). Nevertheless, heterogeneity of cellpopulations and gene expression in primary human tumours is much less well characterised.
EXPERIMENTAL DESIGN:
We performed single cell gene expression analyses on 472 cells isolated from needle biopsies of 5 primary human melanomas, 4 superficial spreading and one acral melanoma. The expression of MITF-high and MITF-low signature genes was assessed and compared to investigate intra and inter-tumoural heterogeneity and correlated gene expression profiles.
RESULTS:
Single cell gene expression analyses revealed varying degrees of intra and inter-tumour heterogeneity conferred by the variable expression of distinct sets of genes in different tumours. Expression of MITF partially correlated with that of its known target genes while SOX10 expression correlated best with PAX3 and ZEB2. Nevertheless, cells simultaneously expressing MITF-high and MITF-low signature genes were observed both by single cell analyses and RNAscope.
CONCLUSIONS:
Single cell analyses can be performed on limiting numbers of cells from primary human melanomas revealing their heterogeneity. While tumours comprised variable proportions of cells with the MITF-high and MITF-low gene expression signatures characteristic of melanoma cultures, primary tumours also comprised cells expressing markers of both signatures defining a novel cell state in tumours in vivo.
Nature
2023 Jun 01
Wang, X;Ramos, R;Phan, AQ;Yamaga, K;Flesher, JL;Jiang, S;Oh, JW;Jin, S;Jahid, S;Kuan, CH;Nguyen, TK;Liang, HY;Shettigar, NU;Hou, R;Tran, KH;Nguyen, A;Vu, KN;Phung, JL;Ingal, JP;Levitt, KM;Cao, X;Liu, Y;Deng, Z;Taguchi, N;Scarfone, VM;Wang, G;Paolilli, KN;Wang, X;Guerrero-Juarez, CF;Davis, RT;Greenberg, EN;Ruiz-Vega, R;Vasudeva, P;Murad, R;Widyastuti, LHP;Lee, HL;McElwee, KJ;Gadeau, AP;Lawson, DA;Andersen, B;Mortazavi, A;Yu, Z;Nie, Q;Kunisada, T;Karin, M;Tuckermann, J;Esko, JD;Ganesan, AK;Li, J;Plikus, MV;
PMID: 37344645 | DOI: 10.1038/s41586-023-06172-8
BMC Biol.
2019 Apr 11
Chandra L, Borcherding DC, Kingsbury D, Atherly T, Ambrosini YM, Bourgois-Mochel A, Yuan W, Kimber M, Qi Y, Wang Q, Wannemuehler M, Ellinwood NM, Snella E, Martin M, Skala M, Meyerholz D, Estes M, Fernandez-Zapico ME, Jergens AE, Mochel JP, Allenspach K.
PMID: 30975131 | DOI: 10.1186/s12915-019-0652-6
Abstract
BACKGROUND:
Large animal models, such as the dog, are increasingly being used for studying diseases including gastrointestinal (GI) disorders. Dogs share similar environmental, genomic, anatomical, and intestinal physiologic features with humans. To bridge the gap between commonly used animal models, such as rodents, and humans, and expand the translational potential of the dog model, we developed a three-dimensional (3D) canine GI organoid (enteroid and colonoid) system. Organoids have recently gained interest in translational research as this model system better recapitulates the physiological and molecular features of the tissue environment in comparison with two-dimensional cultures.
RESULTS:
Organoids were derived from tissue of more than 40 healthy dogs and dogs with GI conditions, including inflammatory bowel disease (IBD) and intestinal carcinomas. Adult intestinal stem cells (ISC) were isolated from whole jejunal tissue as well as endoscopically obtained duodenal, ileal, and colonic biopsy samples using an optimized culture protocol. Intestinal organoids were comprehensively characterized using histology, immunohistochemistry, RNA in situ hybridization, and transmission electron microscopy, to determine the extent to which they recapitulated the in vivo tissue characteristics. Physiological relevance of the enteroid system was defined using functional assays such as optical metabolic imaging (OMI), the cystic fibrosis transmembrane conductance regulator (CFTR) function assay, and Exosome-Like Vesicles (EV) uptake assay, as a basis for wider applications of this technology in basic, preclinical and translational GI research. We have furthermore created a collection of cryopreserved organoids to facilitate future research.
CONCLUSIONS:
We establish the canine GI organoid systems as a model to study naturally occurring intestinal diseases in dogs and humans, and that can be used for toxicology studies, for analysis of host-pathogen interactions, and for other translational applications.
Nature
2017 May 17
Chung S, Weber F, Zhong P, Tan CL, Nguyen TN, Beier KT, Hörmann N, Chang WC, Zhang Z, Do JP, Yao S, Krashes MJ, Tasic B, Cetin A, Zeng H, Knight ZA, Luo L, Dan Y.
PMID: 28514446 | DOI: 10.1038/nature22350
In humans and other mammalian species, lesions in the preoptic area of the hypothalamus cause profound sleep impairment, indicating a crucial role of the preoptic area in sleep generation. However, the underlying circuit mechanism remains poorly understood. Electrophysiological recordings and c-Fos immunohistochemistry have shown the existence of sleep-active neurons in the preoptic area, especially in the ventrolateral preoptic area and median preoptic nucleus. Pharmacogenetic activation of c-Fos-labelled sleep-active neurons has been shown to induce sleep. However, the sleep-active neurons are spatially intermingled with wake-active neurons, making it difficult to target the sleep neurons specifically for circuit analysis. Here we identify a population of preoptic area sleep neurons on the basis of their projection target and discover their molecular markers. Using a lentivirus expressing channelrhodopsin-2 or a light-activated chloride channel for retrograde labelling, bidirectional optogenetic manipulation, and optrode recording, we show that the preoptic area GABAergic neurons projecting to the tuberomammillary nucleus are both sleep active and sleep promoting. Furthermore, translating ribosome affinity purification and single-cell RNA sequencing identify candidate markers for these neurons, and optogenetic and pharmacogenetic manipulations demonstrate that several peptide markers (cholecystokinin, corticotropin-releasing hormone, and tachykinin 1) label sleep-promoting neurons. Together, these findings provide easy genetic access to sleep-promoting preoptic area neurons and a valuable entry point for dissecting the sleep control circuit.
eNeuro
2018 Jan 24
McCullough KM, Morrison FG, Hartmann J, Carlezon WA, Ressler KJ.
PMID: - | DOI: 10.1523/ENEURO.0010-18.2018
Molecular identification and characterization of fear controlling circuitries is a promising path towards developing targeted treatments of fear-related disorders. Three-color in situ hybridization analysis was used to determine whether somatostatin (Sst), neurotensin (Nts), corticotropin releasing factor (Crf), tachykinin 2 (Tac2), protein kinase c delta (Prkcd), and dopamine receptor 2 (Drd2) mRNA co-localize in male mouse amygdala neurons. Expression and co-localization was examined across capsular (CeC), lateral (CeL), and medial (CeM) compartments of the central amygdala. The greatest expression of Prkcd and Drd2 were found in CeC and CeL. Crf was expressed primarily in CeL while Sst, Nts, and Tac2 expressing neurons were distributed between CeL and CeM. High levels of co-localization were identified between Sst, Nts, Crf, and Tac2 within the CeL while little co-localization was detected between any mRNAs within the CeM. These findings provide a more detailed understanding of the molecular mechanisms that regulate the development and maintenance of fear and anxiety behaviors.
Significance Statement Functional and behavioral analysis of central amygdala microcircuits has yielded significant insights into the role of this nucleus in fear and anxiety related behaviors. However, precise molecular and locational description of examined populations is lacking. This publication provides a quantified regionally precise description of the expression and co-expression of six frequently examined central amygdala population markers. Most revealing, within the most commonly examined region, the posterior CeL, four of these markers are extensively co-expressed suggesting the potential for experimental redundancy. This data clarifies circuit interaction and function and will increase relevance and precision of future cell-type specific reports.
Endocrinology
2022 Jan 01
Téblick, A;De Bruyn, L;Van Oudenhove, T;Vander Perre, S;Pauwels, L;Derde, S;Langouche, L;Van den Berghe, G;
PMID: 34698826 | DOI: 10.1210/endocr/bqab222
Cellular & molecular immunology
2023 Jun 26
Silvin, A;Qian, J;Ginhoux, F;
PMID: 37365324 | DOI: 10.1038/s41423-023-01053-6
Nature communications
2021 Jun 11
Luchsinger, JR;Fetterly, TL;Williford, KM;Salimando, GJ;Doyle, MA;Maldonado, J;Simerly, RB;Winder, DG;Centanni, SW;
PMID: 34117229 | DOI: 10.1038/s41467-021-23674-z
Description | ||
---|---|---|
sense Example: Hs-LAG3-sense | Standard probes for RNA detection are in antisense. Sense probe is reverse complent to the corresponding antisense probe. | |
Intron# Example: Mm-Htt-intron2 | Probe targets the indicated intron in the target gene, commonly used for pre-mRNA detection | |
Pool/Pan Example: Hs-CD3-pool (Hs-CD3D, Hs-CD3E, Hs-CD3G) | A mixture of multiple probe sets targeting multiple genes or transcripts | |
No-XSp Example: Hs-PDGFB-No-XMm | Does not cross detect with the species (Sp) | |
XSp Example: Rn-Pde9a-XMm | designed to cross detect with the species (Sp) | |
O# Example: Mm-Islr-O1 | Alternative design targeting different regions of the same transcript or isoforms | |
CDS Example: Hs-SLC31A-CDS | Probe targets the protein-coding sequence only | |
EnEm | Probe targets exons n and m | |
En-Em | Probe targets region from exon n to exon m | |
Retired Nomenclature | ||
tvn Example: Hs-LEPR-tv1 | Designed to target transcript variant n | |
ORF Example: Hs-ACVRL1-ORF | Probe targets open reading frame | |
UTR Example: Hs-HTT-UTR-C3 | Probe targets the untranslated region (non-protein-coding region) only | |
5UTR Example: Hs-GNRHR-5UTR | Probe targets the 5' untranslated region only | |
3UTR Example: Rn-Npy1r-3UTR | Probe targets the 3' untranslated region only | |
Pan Example: Pool | A mixture of multiple probe sets targeting multiple genes or transcripts |
Complete one of the three forms below and we will get back to you.
For Quote Requests, please provide more details in the Contact Sales form below
Our new headquarters office starting May 2016:
7707 Gateway Blvd.
Newark, CA 94560
Toll Free: 1 (877) 576-3636
Phone: (510) 576-8800
Fax: (510) 576-8798
19 Barton Lane
Abingdon Science Park
Abingdon
OX14 3NB
United Kingdom
Phone 2: +44 1235 529449
Fax: +44 1235 533420
20F, Tower 3,
Raffles City Changning Office,
1193 Changning Road, Shanghai 200051
021-52293200
info.cn@bio-techne.com
Web: www.acdbio.com/cn
For general information: Info.ACD@bio-techne.com
For place an order: order.ACD@bio-techne.com
For product support: support.ACD@bio-techne.com
For career opportunities: hr.ACD@bio-techne.com